Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability

• Published in: Fluids and barriers of the CNS Vol. 21; no. 1; p. 36
• Main Authors: Dai, Tingjun, Lou, Jianwei, Kong, Deyuan, Li, Jinyu, Ren, Qingguo, Chen, Yujing, Sun, Sujuan, Yun, Yan, Sun, Xiaohan, Yang, Yiru, Shao, Kai, Li, Wei, Zhao, Yuying, Meng, Xiangshui, Yan, Chuanzhu, Lin, Pengfei, Liu, Shuangwu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.04.2024; BioMed Central; BMC
• Subjects: Albumin; ALS; Alzheimer's disease; Amyotrophic lateral sclerosis; Blood-CSF barrier; Cerebrospinal fluid; Choroid plexus; Comorbidity; Disease; Enlargement; Gene mutations; Genetic screening; Genetic testing; Medical colleges; Medical imaging; Medical research; Medicine, Experimental; MRI; Nervous system diseases; Neurodegenerative diseases; Neuroimaging; Parkinson's disease; Permeability; Proteins; Software; Somatotropin; Variance analysis; Volumetric analysis; Choroid plexus; ALS; MRI; Blood-CSF barrier
• ISSN: 2045-8118; 2045-8118
• DOI: 10.1186/s12987-024-00536-6

Using in vivo neuroimaging techniques, growing evidence has demonstrated that the choroid plexus (CP) volume is enlarged in patients with several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. However, although animal and postmortem findings suggest that CP abnormalities are likely important pathological mechanisms underlying amyotrophic lateral sclerosis (ALS), the third most common neurodegenerative disease, no available study has been conducted to thoroughly assess CP abnormalities and their clinical relevance in vivo in ALS patients to date. Thus, we aimed to determine whether in vivo CP enlargement may occur in ALS patients. We also aimed to identify the relationships of CP volume with clinical disabilities and blood-CSF barrier (BCSFB) permeability in ALS patients. In this retrospective study, based on structural MRI data, CP volume was assessed using a Gaussian mixture model and underwent further manual correction in 155 ALS patients and 105 age- and sex-matched HCs from October 2021 to April 2023. The ALS Functional Rating Scale-Revised (ALSFRS-R) was used to assess clinical disability. The CSF/serum albumin quotient (Qalb) was used to assess BCSFB permeability. Moreover, all the ALS patients completed genetic testing, and according to genetic testing, the ALS patients were further divided into genetic ALS subgroup and sporadic ALS subgroup. We found that compared with HCs, ALS patients had a significantly higher CP volume (p < 0.001). Moreover, compared with HCs, CP volume was significantly increased in both ALS patients with and without known genetic mutations after family-wise error correction (p = 0.006 and p < 0.001, respectively), while there were no significant differences between the two ALS groups. Furthermore, the CP volume was significantly correlated with the ALSFRS-r score (r = -0.226; p = 0.005) and the Qalb (r = 0.479; p < 0.001) in ALS patients. Our study first demonstrates CP enlargement in vivo in ALS patients, and continues to suggest an important pathogenetic role for CP abnormalities in ALS. Moreover, assessing CP volume is likely a noninvasive and easy-to-implement approach for screening BCSFB dysfunction in ALS patients.